Data gathered: August 24
AI Stock Analysis - Annexon (ANNX)
Analysis generated May 21, 2025. Powered by Chat GPT.
Annexon (ANNX) is a biopharmaceutical company focused on developing therapies to treat complement-mediated diseases. The company targets neurodegenerative and autoimmune disorders through its innovative approach to inhibiting C1q, the initiator of the classical complement pathway. Annexon's commitment to groundbreaking research and targeted treatment options positions it uniquely within the biopharmaceutical landscape.
Stock Alerts - Annexon (ANNX)
 |
Annexon | August 22 Price is up by 6.5% in the last 24h. |
|
Annexon | August 19 Price is down by -7.5% in the last 24h. |
|
Annexon | August 14 Price is down by -7.1% in the last 24h. |
|
Annexon | August 13 Price is up by 7.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Annexon
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 92 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Employee Rating | 44 | Sign up | Sign up | Sign up |
| Google Trends | 40 | Sign up | Sign up | Sign up |
| Patents | 14 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 13 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,010 | Sign up | Sign up | Sign up |
| Twitter Followers | 315 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 21 | Sign up | Sign up | Sign up |
| Linkedin Employees | 121 | Sign up | Sign up | Sign up |
About Annexon
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.
| Price | $2.31 |
| Target Price | Sign up |
| Volume | 1,950,000 |
| Market Cap | $238M |
| Year Range | $1.38 - $5.5 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)August 18 - GlobeNewswire |
|
 |
Annexon (NASDAQ:ANNX) Earns “Buy” Rating from HC WainwrightAugust 17 - ETF Daily News |
 |
Annexon reports Q2 EPS (34c), consensus (36c)August 14 - Thefly.com |
 |
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated MilestonesAugust 14 - Yahoo |
 |
Annexon (ANNX) Expected to Announce Quarterly Earnings on MondayAugust 9 - ETF Daily News |
|
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic AtrophyAugust 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 0 | 0 | 0 | -49M | 0 | -0.340 |
| Q1 '25 | 0 | 0 | 0 | -54M | -57M | -0.370 |
| Q4 '24 | 0 | 0 | 0 | -49M | -52M | -0.330 |
| Q3 '24 | 0 | 0 | 0 | -35M | -39M | -0.250 |
| Q2 '24 | 0 | 860,000 | -860,000 | -30M | -33M | -0.230 |
Insider Transactions View All
| Carson William H. filed to buy 33,830 shares at $2.4. August 1 '25 |
| Overdorf Michael filed to sell 130,689 shares at $2.6. July 16 '25 |
| Lew Jennifer filed to sell 121,616 shares at $2.6. July 16 '25 |
| Yednock Ted filed to sell 105,084 shares at $2.6. July 16 '25 |
| Carson William H. filed to buy 29,715 shares at $2.5. July 1 '25 |
Similar companies
Read more about Annexon (ANNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Annexon?
The Market Cap of Annexon is $238M.
What is the current stock price of Annexon?
Currently, the price of one share of Annexon stock is $2.31.
How can I analyze the ANNX stock price chart for investment decisions?
The ANNX stock price chart above provides a comprehensive visual representation of Annexon's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Annexon shares. Our platform offers an up-to-date ANNX stock price chart, along with technical data analysis and alternative data insights.
Does ANNX offer dividends to its shareholders?
As of our latest update, Annexon (ANNX) does not offer dividends to its shareholders. Investors interested in Annexon should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Annexon?
Some of the similar stocks of Annexon are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.